Managing ocular surface disease in patients with glaucoma
Take-home message: Treating ocular surface disease may have an impact on the effectiveness of glaucoma treatment. Inder Paul Singh, MD, offers some strategies used in practice.
Ocular surface disease (OSD) is an extremely common entity, so it should be no surprise that it can frequently be found in patients with glaucoma.
Ocular surface disease index (OSDI) scores are normal in about 41% of patients with glaucoma, demonstrate mild to moderate dry eye disease (DED) in about 33%, and severe dry eye in 26%.1
A study by Rossi and colleagues reviewing tear break up time (TBUT), corneal staining, and OSDI scores in patients with glaucoma grouped patients into four categories.2 Five percent of those on zero medications had DED; 11% on one medication had DED; 39% on two medications had DED; and 40% of those on three medications had DED.
The conclusion is obvious: The more medications that patients take, the more likely it is for patients to complain or exhibit signs of dry eye.
Read the rest of the article on Ophthamology Times website